Home   |   About Us   |   Research & Development   |   Clinical Trials   |   News   |   Contact Us 

Research & Development

Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.


Product Pipeline

Glycadia's proprietary new chemical entities include:


Product Indication Preclinical Clinical
      Phase I Phase II Phase III
GLY-230 Diabetic Nephropathy
GLY-230 Diabetic Retinopathy    
GLY-220 Macrovascular Disease      
A717 Diabetic Nephropathy      
A717 Diabetic Retinopathy      
CAP22 Macrovascular Disease      
GLY-230 Alzheimer's Disease      




Glycadia Pharmaceuticals          1880 JFK Blvd, Suite 200          Philadelphia, PA 19103
Tel 215.557.8021          Fax 215.557.8053



Developing safe and effective treatments for diabetic complications.™